Athenex Inc (NASDAQ:ATNX)

3.40
BATS BZX Real-Time Price
As of 1:12pm ET
 +0.08 / +2.41%
Today’s Change
3.12
Today|||52-Week Range
15.00
-69.26%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$380.4M

Company Description

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Contact Information

Athenex, Inc.
1001 Main Street
Buffalo New York 14203
P:(716) 427-2950
Investor Relations:

Employees

Shareholders

Other institutional27.17%
Individual stakeholders27.08%
Mutual fund holders19.49%

Top Executives

Yiu Nam LauChairman & Chief Executive Officer
Jeffrey M. YordonCOO & President-Athenex Pharmaceutical Division
Steven AdamsController, Chief Financial & Accounting Officer
Rudolf KwanChief Medical Officer
Teresa BairSecretary, SVP-Administration & General Counsel